All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, What is the risk of losing response to ruxolitinib over time?
REACH2 study: What is the risk of losing response to ruxolitinib over time?
In this video, Mohty reports on a follow-up from the phase III REACH2 trial, comparing the use of ruxolitinib as salvage treatment versus best available therapy for patients with steroid-refractory acute GvHD.
New working definition of ruxolitinib-refractory acute GvHD
Mohamad Mohty, chair of the GvHD Hub Steering Committee, and colleagues published an article in Blood to define the patient population that can now be considered ruxolitinib-refractory, in...
Updated results from REACH2: Ruxolitinib for steroid-refractory acute GvHD
As previously reported on the GvHD Hub, the initial data from the phase III REACH2 trial uncovered the potential benefit of ruxolitinib over best available treatment (BAT) for...
Subscribe to get the best content related to GvHD delivered to your inbox